HJ Science Co., Ltd.
華健未來（成都）科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6132)

(1) PROPOSED ADOPTION OF THE 2026 H SHARE INCENTIVE SCHEME
(2) PROPOSED CHANGE OF COMPANY NAME
(3) PROPOSED AMENDMENTS TO THE ARTICLES
(4) CHANGE OF NON-EXECUTIVE DIRECTORS

(1) PROPOSED ADOPTION OF THE 2026 H SHARE INCENTIVE SCHEME

The board (the "**Board**") of directors (the "**Directors**") of HJ Science Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") has resolved, subject to conditions precedents set out below, the adoption of the H share incentive scheme (the "**Scheme**").

The Scheme will constitute a scheme under Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

The Scheme becoming effective is conditional upon (i) the passing of a special resolution by the Shareholders at the upcoming extraordinary general meeting (the "**EGM**") to approve the adoption of the Scheme; and (ii) the Listing Committee of the Stock Exchange granting approval of the listing of, and permission to deal in, the H shares to be allotted and issued pursuant to the awards granted under the Scheme.

Details of the terms and conditions of the Scheme will be set out in the circular of the Company, which will be despatched to the Shareholders in due course.

(2) PROPOSED CHANGE OF COMPANY NAME

The Board proposes to change the name of the Company as follows (the "**Change of Company Name**"):

Original Company name: 華健未來(成都)科技股份有限公司 (HJ Science Co., Ltd.)

Proposed Company Name: 華健未來(成都)生物科技股份有限公司 (HJ Science Co., Ltd.)

The proposed Change of Company Name is conditional upon the satisfaction of (i) the passing of a special resolution by the Shareholders at the EGM approving the Change of Company Name and the corresponding amendments to the articles of association of the Company (the "**Articles**"); and (ii) the obtaining or completion of all necessary approvals or filings in respect of the proposed Change of Company Name with the relevant PRC regulatory authorities.

The Board believes that the proposed name "華健未來(成都)生物科技股份有限公司" as the Company's name is able to both embody the characteristics of the biopharmaceutical industry and fully maintain the continuity of the operational resources associated with this brand identity. The Board considers that the proposed Change of Company Name is in the interests of the Company and Shareholders as a whole.

(3) PROPOSED AMENDMENTS TO THE ARTICLES

The Board proposes to seek the approval of the Shareholders at the upcoming EGM to amend its Articles to reflect (1) the changes in the registered capital and the total number of issued shares of the Company after the listing of the H Shares; (2) subject to the approval by the Shareholders of the Change of Company Name, the new Company name of the Company; and (3) the updated number of Directors. Save for the proposed amendments, other provisions of the Articles remain unchanged. The proposed amendments will be set out in detail in the circular of the Company for the upcoming EGM.

(4) CHANGE OF NON-EXECUTIVE DIRECTORS

(i) Proposed appointment of non-executive Directors

The Board is pleased to announce that, Mr. Wang Liyuan (**"Mr. Wang"**) and Mr. Fang Shengshi ("**Mr. Fang**") have been nominated, for election by the Shareholders, as non-executive Directors of the Company.

Their term of office, if approved by the Shareholders at the forthcoming EGM, will commence from the date on which the relevant resolution is passed at the EGM until the expiration of the term of the current Board.

The biographical details of Mr. Wang and Mr. Fang are set out below:

Mr. Wang Liyuan, aged 48, is currently the chairman of Huada (Chongqing) Private Equity Investment Fund Management Co., Ltd. (華達(重慶)私募股權投資基金管理有限公司), deputy secretary of the party committee of West (Chongqing) Science City Jiangjin Park Development and Construction Group Co., Ltd. (西部(重慶)科學城江津園區開發建設集團有限公司), and general manager of Chongqing Jiangjin Science and Technology Innovation Industry Development Co., Ltd. (重慶江津科創產業發展有限公司).

Mr. Wang has extensive experience in government economic administration, industrial park management, financing services and investment management.

He previously held various senior roles in the Jiangjin District (江津市) government and related entities from 1998 to 2025, including Deputy Director and Party Committee member of the Chongqing Jiangjin District Economic and Information Commission (重慶市江津區經濟信息委), Deputy General Manager of Chongqing Jiangjin District Huaxin Asset Management (Group) Co., Ltd. (重慶市江津區華信資產經營(集團)有限公司), and other senior positions in science and technology investment and construction companies under the Jiangjin District Government.

Mr. Wang obtained a bachelor's degree in law from the Central Radio and Television University (now The Open University of China) in 2006.

Mr. Wang will not receive any director fees from the Company as non-executive Director.

As at the date of this announcement, Mr. Wang (i) does not have any relationship with any Directors, senior management or substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) is not interested in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iii) does not hold any position in the Company or any subsidiary of the Company, nor any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this announcement respectively.

Save as disclosed above and as at the date of this announcement, there is no other information in relation to Mr. Wang which is required to be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to (v) of the Listing Rules, nor are there any other matters which need to be brought to the attention of the Shareholders.

Mr. Fang Shengshi, aged 38, is currently a partner and project management director of Ningbo Huaige Health Investment Management Partnership (Limited Partnership) (寧波懷格健康投資管理合夥企業(有限合夥)).

Mr. Fang has extensive experience in audit, investment and financial management. From August 2010 to October 2015, Mr. Fang worked at BDO China Shu Lun Pan Certified Public Accountants LLP (立信會計師事務所特殊普通合夥), during which he was responsible for auditing. From October 2015 to December 2016, Mr. Fang was the vice president of Shanghai Jisheng Equity Investment Management Co., Ltd. (上海紀升股權投資管理有限公司) overseeing project financing and providing financial consulting services. Since January 2017, Mr. Fang has served as an investment director at Shanghai Huaige Industrial Development Co., Ltd. (上海懷格實業發展有限公司). Mr. Fang also holds various directorships in other healthcare and investment companies, including Ningbo Huaige Medical Investment Management Co., Ltd. (寧波懷格醫療投資管理有限公司) since July 2017 and Shanghai Zhiting Medical Technology Co., Ltd. (上海志聽醫療科技有限公司) since March 2023. Mr. Fang is also a supervisor of Hunan Yineng Biopharmaceutical Co., Ltd. (湖南易能生物醫藥有限公司) since April 2023.

Mr. Fang obtained a bachelor's degree in management from Shanghai Lixin University of Accounting and Finance (formerly known as Shanghai Lixin Institute of Commerce) in Shanghai, the PRC in July 2010. He is a Certified Public Accountant and a Certified Tax Agent in the PRC. He also holds the Legal Professional Qualification Certificate in the PRC.

As at the date of this announcement, Mr. Fang holds 15,000 H shares of the Company.

Mr. Fang will not receive any director fees from the Company as non-executive Director.

Save as disclosed above and as at the date of this announcement, Mr. Fang (i) does not have any relationship with any Directors, senior management or substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) is not interested in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iii) does not hold any position in the Company or any subsidiary of the Company, nor any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this announcement respectively.

Save as disclosed above and as at the date of this announcement, there is no other information in relation to Mr. Fang which is required to be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to (v) of the Listing Rules, nor are there any other matters which need to be brought to the attention of the Shareholders.

The Board would like to extend its warm welcome to Mr. Wang and Mr. Fang on their respective new appointments.

(ii) Resignation of non-executive Directors

The Board announces that each of Mr. Wang Junfeng ("**Mr Wang**"), Mr. Zhang Zhiyong ("**Mr. Zhang**") and Mr. Du Jiangbo ("**Mr. Du**") has tendered his resignation as a non-executive Director to devote more time and dedication to their respective other personal commitments, all with effect upon the conclusion of the EGM.

Each of Mr. Wang Junfeng, Mr. Zhang and Mr. Du has confirmed that he has no disagreement with the Board and there are no other matters relating to their resignations that need to be brought to the attention of the holders of securities of the Company.

The Board would like to take this opportunity to express its gratitude to Mr. Wang Junfeng, Mr. Zhang and Mr. Du for their contribution to the Group during the tenure of their offices.

A circular containing, among other things, information relating to, among others, the proposed adoption of the Scheme, the proposed Change of Company Name, the proposed amendments to the Articles, the proposed appointment of Directors, the notice convening the EGM together with the proxy form will be despatched to the Shareholders in due course.

By order of the Board
HJ Science Co., Ltd.
Dr. Ji Jianxin
Executive Director, chairman of the Board,
chief executive officer and general manager

Hong Kong, 17 August, 2026

As at the date of this announcement, the executive Directors are Dr. Ji Jianxin, Mr. Yang Xiangyu, Mr. Wu Zhen and Ms. Zhang Yao; the non-executive Directors are Ms. Geng Xueli, Mr. Du Jiangbo, Mr. Wang Junfeng and Mr. Zhang Zhiyong; and the independent non-executive Directors are Mr. Wong Jovi Chi Wing, Mr. Jiang He, Ms. Lin Fangzhu and Mr. Liu Zhe.